Holen Sie sich die Stockscreener-App
16.77
0.09%
0.035
Schlusskurs vom Vortag:
$16.81
Offen:
$16.8
24-Stunden-Volumen:
261.07K
Relative Volume:
0.07
Marktkapitalisierung:
$12.51B
Einnahmen:
$220.00K
Nettoeinkommen (Verlust:
$-746.08M
KGV:
-16.65
EPS:
-1.0074
Netto-Cashflow:
$-211.81M
1W Leistung:
-10.65%
1M Leistung:
-19.84%
6M Leistung:
-29.93%
1J Leistung:
-15.88%
1-Tages-Spanne:
$16.54
$17.02
1-Wochen-Bereich:
$16.45
$18.90
52-Wochen-Spanne:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Vergleichen Sie SMMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
16.78 | 12.51B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
ARGX
Argen X Se Adr
|
925.25 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.28 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.66 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ONC
Beone Medicines Ltd Adr
|
351.97 | 40.27B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
719.33 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Barclays | Underweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Neutral |
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying (NASDAQ:SMMT) - Seeking Alpha
Has Summit Therapeutics Inc. found a price floorJuly 2025 Trends & Free Weekly Chart Analysis and Trade Guides - newser.com
Wolfe Research Initiates Coverage of Summit Therapeutics (SMMT) with Peer Perform Recommendation - Nasdaq
Summit Therapeutics at Jefferies London: Strategic Progress in Cancer Trials By Investing.com - Investing.com Canada
Wolfe Research Initiates Coverage on SMMT with 'Peer Perform' Ra - GuruFocus
Transcript : Summit Therapeutics Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 03 - MarketScreener
What institutional flow reveals about Summit Therapeutics Inc.GDP Growth & Real-Time Buy Zone Alerts - newser.com
What MACD and RSI say about Summit Therapeutics Inc.July 2025 Closing Moves & Advanced Swing Trade Entry Alerts - newser.com
Is Summit Therapeutics Inc. building a consolidation baseWeekly Investment Recap & Verified Stock Trade Ideas - newser.com
News impact scoring models applied to Summit Therapeutics Inc.Options Play & Technical Pattern Alert System - newser.com
Is Summit Therapeutics Inc. showing signs of accumulationJuly 2025 Pullbacks & High Yield Stock Recommendations - newser.com
Should you hold or exit Summit Therapeutics Inc. nowJuly 2025 Highlights & Free Verified High Yield Trade Plans - newser.com
Is Summit Therapeutics Inc. stock a safe haven assetForecast Cut & Short-Term High Return Ideas - Fundação Cultural do Pará
Analyzing Summit Therapeutics Inc. with risk reward ratio chartsWeekly Trend Summary & Community Trade Idea Sharing Platform - newser.com
Can Summit Therapeutics Inc. hit a new high this monthInsider Selling & Weekly Return Optimization Plans - newser.com
Summit Therapeutics (SMMT) Reports Positive Results from the Phase III HARMONi Trial - Yahoo Finance
Responsive Playbooks and the SMMT Inflection - news.stocktradersdaily.com
Summit and Akeso ivonescimab’s shows significant OS benefit - The Pharma Letter
Clear Street Remains a Buy on Summit Therapeutics (SMMT) - The Globe and Mail
Insiders Are Buying These 3 Stocks Hand Over Fist - AOL.com
Summit Therapeutics Reports Positive Phase III Trial Results - MSN
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China - Placera.se
Summit Therapeutics Says Ivonescimab, Chemotherapy Combination Shows Benefit in Treating Lung Cancer - MarketScreener
Summit Therapeutics Inc Reports Positive Phase III Trial Results - TradingView
[8-K] Summit Therapeutics Inc. Reports Material Event | SMMT SEC FilingForm 8-K - Stock Titan
Summit (NASDAQ: SMMT): ivonescimab combo OS 16.8 vs 14.1 mo in EGFRm NSCLC - Stock Titan
Will Summit Therapeutics Inc. stock outperform growth indexesSwing Trade & Verified Short-Term Trading Plans - fcp.pa.gov.br
Applying sector rotation models to Summit Therapeutics Inc.Weekly Profit Analysis & AI Powered Market Entry Strategies - newser.com
Transforming Lung Cancer Care Through Targeted Science and Patient-First InnovationSummit Therapeutics - Oncodaily
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Summit Therapeutics Inc-Aktie (SMMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
1.14%
2.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):